A platform company
Linking pharmaceutical innovation and
commercialization with strong product
lifecycle management capability
commercialization with strong product
lifecycle management capability
Focusing on our advantageous specialty areas, targeting unmet clinical needs, we continuously identify and develop first-in-class (FIC) and best-in-class (BIC) innovative products.
Upholding clinical value as the core, we deliver competitive products and services that enhance disease diagnosis and treatment as well as clinical practice, ultimately benefiting patients.
At a time of annual review and year-end conclusion, a number of major capital market events and award selections have been held intensively, and CMS has received two significant honors. On January 9, at the 2025 Hong Kong Wealth Management Summit and the 12th “Top 100 Hong Kong Listed Companies” Awards Ceremony, CMS was honored as the “Top 100 Hong Kong Listed Companies-Annual Pharmaceutical and Healthcare Innovation Pioneer”. Previously, on December 29, at the 2025 CLS 8th Investment Summit and the “Capital Market Most Value-Influential List” Awards Ceremony, CMS also received the “Most Investment Value Award”. Receiving two authoritative awards in short succession fully demonstrates the market’s high recognition of the Group’s comprehensive strength and long-term development value. As a highly credible selection event in the Hong Kong stock market, the “Top 100 Hong Kong Listed Companies” aims to identify companies listed on the Main Board with sound development […]
We collaborate with global innovative companies in flexible structures to jointly build a pharmaceutical ecosystem in a sustainable and collaborative setting for the benefit of all stakeholders.
If you are interested in joining us, or curious about our business and products, please feel free to contact us.